Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ)
CNY24.62
+0.78 (+3.27%)
CN SHZ Healthcare Drug Manufacturers - General
Address
No. 636, Zhiyuan North Road 313200
Huzhou, CN
Huzhou, CN
CEO
Jianming He
Website
wolwobiotech.com
IPO
2014-01-21
ISIN CNE100001R58
Description
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. operates as a biopharmaceutical enterprise, primarily engaged in the discovery, development, production, and sale of medicinal products. The company's core focus is on pharmaceuticals designed for the diagnosis and management of allergic conditions, which it supplies to both the Chinese domestic market and international clientele. Additionally, its portfolio encompasses various skincare lines and stem cell-related solutions. The firm's main offices are located in Huzhou, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY24.62
+0.78 (+3.27%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
10M
Beta
0.39
Float Shares
263.14M
Free Float %
50.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.08% | -3.34% | -11.06% | -15.77% | -28.26% | -20.32% | +11.94% | -41.42% | -67.07% | +115.76% | +301.96% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
24.62
DCF (Unlevered)
16.14
-34.4%
DCF (Levered)
19.03
-22.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | +1 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
67.98
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
7 / 10
Strong MOAT
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✓ MOAT relativo
★ Strong MOAT
-
Revenue growth Drug Manufacturers - General: +6.6%+14.8% ★ Q1'26: +10.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%+19.7% ★ Q1'26: +62.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+34.4% ★ Q1'26: +14.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+40.8% ★ Q1'26: +52.2% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+26.9% ★ Q1'26: +30.8% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×0.03× ★ Q1'26: 0.03× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 4 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
267.11M
est: 272.00M (-1.8%)
|
312.09M
est: 296.00M (+5.4%)
|
385.58M
est: 386.00M (-0.1%)
|
500.74M
est: 501.50M (-0.2%)
|
639.35M
est: 647.16M (-1.2%)
|
636.21M
est: 655.60M (-3.0%)
|
807.69M
est: 808.00M (0.0%)
|
896.02M
est: 860.00M (+4.2%)
|
848.19M
est: 891.15M (-4.8%)
|
925.39M
est: 930.00M (-0.5%)
|
1.06B
est: 1.09B (-2.4%)
|
1.20B
1.18B – 1.21B
+9.8% YoY
|
1.40B
1.33B – 1.46B
+17.1% YoY
|
1.65B
1.64B – 1.65B
+17.5% YoY
|
| EBITDA |
131.54M
est: 117.20M (+12.2%)
|
153.86M
est: 127.54M (+20.6%)
|
210.00M
est: 166.32M (+26.3%)
|
259.68M
est: 216.09M (+20.2%)
|
326.87M
est: 278.85M (+17.2%)
|
294.68M
est: 282.49M (+4.3%)
|
366.11M
est: 348.16M (+5.2%)
|
402.44M
est: 370.57M (+8.6%)
|
338.38M
est: 383.51M (-11.8%)
|
360.81M
est: 400.23M (-9.8%)
|
489.25M
est: 468.66M (+4.4%)
|
514.42M
507.79M – 521.04M
+9.8% YoY
|
602.50M
572.96M – 627.71M
+17.1% YoY
|
708.22M
706.89M – 709.55M
+17.5% YoY
|
| EBIT |
127.38M
est: 108.76M (+17.1%)
|
148.16M
est: 118.35M (+25.2%)
|
204.04M
est: 154.34M (+32.2%)
|
252.43M
est: 200.52M (+25.9%)
|
316.50M
est: 258.76M (+22.3%)
|
279.66M
est: 262.14M (+6.7%)
|
346.02M
est: 323.08M (+7.1%)
|
382.07M
est: 343.87M (+11.1%)
|
306.95M
est: 350.70M (-12.5%)
|
317.36M
est: 365.99M (-13.3%)
|
433.50M
est: 428.56M (+1.2%)
|
470.41M
464.35M – 476.47M
+9.8% YoY
|
550.95M
523.95M – 574.01M
+17.1% YoY
|
647.63M
646.42M – 648.85M
+17.5% YoY
|
| Net Income |
117.82M
est: 122.82M (-4.1%)
|
129.20M
est: 135.74M (-4.8%)
|
186.10M
est: 185.84M (+0.1%)
|
232.88M
est: 238.52M (-2.4%)
|
298.30M
est: 350.80M (-15.0%)
|
278.45M
est: 297.40M (-6.4%)
|
337.99M
est: 340.33M (-0.7%)
|
348.77M
est: 379.60M (-8.1%)
|
310.18M
est: 310.81M (-0.2%)
|
317.82M
est: 345.60M (-8.0%)
|
380.94M
est: 402.11M (-5.3%)
|
453.00M
432.78M – 468.91M
+12.7% YoY
|
522.22M
501.29M – 543.14M
+15.3% YoY
|
613.00M
607.24M – 628.36M
+17.4% YoY
|
| SGA |
123.22M
est: 116.66M (+5.6%)
|
148.27M
est: 126.95M (+16.8%)
|
153.96M
est: 165.55M (-7.0%)
|
199.77M
est: 215.08M (-7.1%)
|
252.63M
est: 277.55M (-9.0%)
|
258.06M
est: 281.17M (-8.2%)
|
333.97M
est: 346.53M (-3.6%)
|
359.63M
est: 368.84M (-2.5%)
|
385.28M
est: 350.22M (+10.0%)
|
434.65M
est: 365.49M (+18.9%)
|
240.34M
est: 427.98M (-43.8%)
|
469.77M
463.72M – 475.82M
+9.8% YoY
|
550.20M
523.23M – 573.22M
+17.1% YoY
|
646.75M
645.53M – 647.96M
+17.5% YoY
|
| EPS |
0.23
est: 0.23 (-4.0%)
|
0.25
est: 0.26 (-4.8%)
|
0.35
est: 0.35 (0.0%)
|
0.44
est: 0.46 (-2.4%)
|
0.57
est: 0.67 (-14.9%)
|
0.53
est: 0.57 (-6.7%)
|
0.65
est: 0.65 (-0.7%)
|
0.67
est: 0.73 (-8.1%)
|
0.59
est: 0.59 (-0.6%)
|
0.61
est: 0.64 (-4.7%)
|
0.73
est: 0.77 (-5.2%)
|
0.86
0.83 – 0.90
+12.1% YoY
|
1.00
0.96 – 1.04
+15.8% YoY
|
1.18
1.16 – 1.20
+18.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-25 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-15 | A | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-14 | A | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-29 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
390.95M
OE per share TTM
0.75
Owner's Yield
3.31%
Maintenance CapEx ratio
3.90%
Maint CapEx / Avg PPE
60.4%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 26 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Franklin FTSE China ETF FLCH | 0.01% | 23.0K | 0.19% |
| 2 | Franklin FTSE China UCITS ETF FLXC.L | 0.01% | 106.6K | 0.19% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 241.1K | 0.39% |
| 4 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 187.3K | 0.06% |
| 5 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 110.9K | 0.29% |
| 6 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 120.1K | 0.28% |
| 7 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 13.6K | 0.48% |
| 8 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 30.6K | 0.26% |
| 9 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.51M | 0.06% |
| 10 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.00% | 41.4K | 0.17% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
258.2K
Shares Outstanding
523.58M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Guoqi Wang | Financial Manager & Head of Accounting Department | — | male |
| Jianming He | General Manager | — | male |
| Long Ji | Deputy Manager of the Marketing Department & Employee Representative Director | — | male |
| Mushuang Hu | Deputy General Manager | — | female |
| Zhenwei Guan | Deputy GM & Secretary of the Board of Directors | — | male |
| Ziqiang Bi | Deputy GM & Non-Independent Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300357.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
